Deputy Chief Physician **Specialty Expertise:** Diagnosis and treatment of gastrointestinal tumors, including esophageal cancer, gastric cancer, colorectal cancer, hepatobiliary and pancreatic tumors, neuroendocrine tumors, and gastrointestinal stromal tumors. Participated in multiple international and domestic multicenter clinical studies on drug therapy or comprehensive treatment. **Key Professional Affiliations:** Standing Committee Member, Youth Expert Committee, Chinese Society of Clinical Oncology (CSCO) Standing Committee Member, Geriatric Oncology Committee, Chinese Anti-Cancer Association (CACA) Member and Secretary, Esophageal Cancer Committee, Beijing Cancer Prevention and Treatment Society Member and Secretary, Clinical Oncology Committee, Chinese Women Doctors Association **Representative Achievements:** 1. National Natural Science Foundation of China, Major Research Plan, 92159106, Establishment of a Precision Assessment Model for Tertiary Lymphoid Structures in Esophageal Squamous Cell Carcinoma and Its Guiding Role in Immunotherapy, 2022-01-01 to 2024-12-31, 600,000 RMB, Funding Period Completed, Participant 2. Y. Cao; S. Qin; S. Luo; Z. Li; Y. Cheng; Y. Fan; Y. Sun; X. Yin; X. Yuan; W. Li; T. Liu; C.-H. Hsu; X. Lin; S.-B. Kim; T. Kojima; J. Zhang; S.-H. Lee; Y. Bai; K. Muro; T. Doi; C. Bai; K. Gu; H.-M. Pan; L. Bai; J.-W. Yang; Y. Cui; W. Lu; J. Chen ; Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia, ESMO Open, 2022, 7(1): 100341 (Journal Article) (Author's Note: Sole First Author, Sole Corresponding Author) 3. Yanshuo Cao; Ming Lu; Yu Sun; Jifang Gong; Jie Li1; Zhihao Lu; Jian Li; Xiaotian Zhang; Yan Li; Zhi Peng; Jun Zhou; Xicheng Wang; Lin Shen; Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial, Journal of Cancer Research and Clinical Oncology, 2022, 149(2023): 779-789 (Journal Article) (Author's Note: Co-First Author)